Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol

M Snir1, U Reich, R Siegel

  • 1Unit of Pediatric Ophthalmology, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel. msnir@clalit.org.il

Eye (London, England)
|September 17, 2011
PubMed

Insights

Oral propranolol effectively treats infantile periocular capillary haemangioma, reducing lesion size and improving astigmatism. This treatment is recommended for its significant benefits in preventing disfigurement.

Area of Science:

  • Ophthalmology
  • Pediatric Medicine
  • Dermatology

Background:

  • Infantile periocular capillary haemangioma presents a significant risk for visual impairment and facial disfigurement.
  • Early intervention is crucial for managing these benign vascular tumors in infants.

Purpose of the Study:

  • To assess the anatomical and optical outcomes of oral propranolol therapy for infantile periocular capillary haemangioma.
  • To evaluate the efficacy of propranolol in resolving periocular haemangiomas and their impact on ocular structures.

Main Methods:

  • A cohort of 30 infants with periocular capillary haemangioma received comprehensive evaluations and oral propranolol treatment.
  • Treatment involved a dosage of 2 mg/kg/day, with regular clinical follow-ups until lesion resolution.
  • Key outcome measures included changes in lesion size, refractive sphere, and cylindrical power.

Main Results:

  • Significant reduction in the involved extraocular area was observed (P<0.0001).
  • Post-treatment, a reduction in mean cylindrical power (astigmatism) in involved eyes was noted (P=0.02).
  • Statistically significant differences in astigmatism and spherical power were found between treated and untreated eyes.

Conclusions:

  • Early diagnosis and prompt propranolol treatment are effective in reducing periocular haemangioma size and correcting astigmatism.
  • Propranolol therapy prevents ocular and facial disfigurement without rebound effects.
  • Oral propranolol is recommended as a preferred treatment for infantile periocular capillary haemangioma.
Abstract